The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
MHLW Finds 57 Suspected Violations in Drug Detailing Activities in FY2019
The Ministry of Health, Labor and Welfare (MHLW) found a total of 57 suspected violations in sales reps’ ethical drug advertising activities in an eight-month period in FY2019. The MHLW received a total of 71 reports of questionable advertising, including…
To read the full story
Related Article
- 26 Suspected Violations in Detailing Activities Reported in FY2021: MHLW
August 12, 2022
- Sharp Drop in Suspected Violations Seen in FY2020 Drug Promotion, but Comparison Difficult due to COVID-19: MHLW
August 23, 2021
- MHLW Wants to Encourage Non-Monitoring Facilities to Report Inappropriate Drug Promotion
January 29, 2021
- MHLW Sets Up New Office to Take Reports on Inappropriate Detailing Activities from Healthcare Providers
October 3, 2019
- 74 Suspected Violations Found in Sales Reps’ Advertising Activities: MHLW
May 21, 2019
REGULATORY
- LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
- Japan Set to Raise Medical Fees by 3% in FY2026, Cut Drug Prices by 0.8%
December 22, 2025
- LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
December 22, 2025
- OTC-Like Drugs Left in Limbo as Panel Debates Cost-Sharing without Clear Policy Signal
December 19, 2025
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…